Autism Spectrum Disorders (ASD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Autism Spectrum Disorders (ASD)

Autism Spectrum Disorders (ASD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Autism spectrum disorder (ASD) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person's life. It affects how a person acts and interacts with others, communicates, and learns.

Epidemiology- Thelansis estimates about 1.68% of United States (US) children aged 8 years (or 1 in 59 children) are diagnosed with ASD. In the US, parent-reported ASD diagnoses in 2016 averaged slightly higher at 2.5%. The prevalence of ASD in the US more than doubled between 2000–2002 and 2010–2012 according to Autism and Developmental Disabilities Monitoring Network (ADDM) estimates. It may be too early to comment on trends, in the US, the prevalence of ASD has appeared to stabilize with no statistically significant increase from 2014 to 2016. Changing diagnostic criteria may impact prevalence and the full impact of the DSM-5 diagnostic criteria has yet to be seen.

Competitive landscape of Autism Spectrum Disorders (ASD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Autism Spectrum Disorders (ASD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Autism Spectrum Disorders (ASD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Autism Spectrum Disorders (ASD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Asset        Company        Stage

Rispe+A16:B32rdal        Johnson & Johnson (JNJ)        Approved (Generic Competition)

Abilify (Oral and IM)        Otsuka Holdings Co., Ltd. (4768:JP)        Approved

Balovaptan        Roche Holding AG (RHHBY)        III

CM-AT        Curemark, LLC        III

Latuda        Sumitomo Dainippon Pharma Co., Ltd.        III

JNJ-42165279        Johnson & Johnson (JNJ)        II

L1-79        Yamo Pharmaceuticals        II

Namenda XR        Allergan plc (AGN)        II

Syntocinon Nasal Spray        Vyera Pharmaceuticals, LLC        II

Zygel        Zynerba Pharmaceuticals, Inc. (ZYNE)        II

AB-2004        Axial Biotherapeutics, Inc.        I/II

RG7816        Roche Holding AG (RHHBY)        I

RVT-701        Roivant Sciences, Inc.        I

GWP42006        GW Pharmaceuticals plc (GWPH)        IND

CP101        Finch Therapeutics Group        Investigator Initiated

Kuvan        BioMarin Pharmaceutical Inc. (BMRN)        Investigator Initiated

Nuedexta        Otsuka Holdings Co., Ltd. (4768:JP)        Investigator Initiated

MSC-exo        Stem Cell Medicine Ltd.        Development Outside U.S.

OPN300        OptiNose, Inc. (OPTN)        Development Outside U.S.

Vafidemstat        Oryzon Genomics S.A. (ORY:SM)        Development Outside U.S.

Allergan/Rugen Autism Program        Rugen Therapeutics        Preclinical

BTRX-323511        BlackThorn Therapeutics, Inc.        Preclinical

Cannabidiol (INSYS)        INSYS Therapeutics, Inc. (INSY)        Preclinical

ENT-02        Enterin Inc.        Preclinical

MD-1103        MedDay Pharmaceuticals        Preclinical

NurOwn        BrainStorm Cell Therapeutics Inc. (BCLI)        Preclinical

QBM-001        Q BioMed Inc. (QBIO)        Preclinical